Semaglutide and Tirzepatide, groundbreaking medications, redefine weight loss by activating specific hormone receptors. These innovations offer effective solutions for achieving and maintaining a healthy weight, transforming the landscape of personalized weight management.
337-988-4116
Call to Schedule appointment now
Characterized as a chronic ailment with potential severe consequences like heart disease, stroke, and diabetes, obesity remains a challenging health condition. While recognized as a treatable chronic disease, individuals managing obesity encounter various hurdles in their journey toward health and weight management. The introduction of new treatment options brings hope to those wrestling with obesity, offering improved alternatives for effective weight management.
The approval originated on the findings obtained from the SURMOUNT-1 and SURMOUNT-2 phase 3 reports. People receiving Zepbound as an addition to diet and exercise showed significant weight loss at 72 weeks compared with placebo in SURMOUNT-1, a trial including 2,539 individuals with obesity, excess weight, and weight-related medical issues excluding diabetes. Zepbound users lost an average of 48 pounds at the maximum dosage (15 mg) and 34 lbs. at the lowest dose (5 mg).
In a groundbreaking achievement for modern weight management, the U.S. Food and Drug Administration has approved semaglutide injection (2.4 mg once weekly) this year. Marking the first FDA-approved drug for chronic weight management in adults dealing with obesity or overweight since 2014, this under-the-skin injection signifies a new era of innovative solutions. Customized to complement a reduced-calorie diet and increased physical activity, it represents a stylish and effective approach to tackling weight challenges in 2023.
“The new treatment option that was approved today can be incorporated into a weight management program to help adults who are obese or overweight,” stated John Sharretts, M.D., deputy director of the FDA’s Center for Drug Evaluation and Research’s Division of Diabetes, Lipid Disorders, and Obesity.”
“The FDA is still dedicated to supporting the creation and authorization of new, safe, and efficacious treatments for adults who suffer from obesity or overweight.” “Diabetes, heart disease, stroke, and other major health problems can be brought on by obesity, a chronic illness.
Joe Nadglowski, president and chief executive officer of the Obesity Action Coalition, stated, “People living with obesity still face many challenges in their health and weight management journey, despite the fact that obesity is a chronic illness that can be treated.
“
Individuals grappling with obesity and searching for improved methods to control their weight might find optimism in the emerging treatment options at their disposal. The outcomes of the SURMOUNT-1 and SURMOUNT-2 phase 3 trials served as the foundation for the approval. Zepbound users who used the medication in addition to diet and exercise for 72 weeks lost a significant amount of weight as compared to placebo participants in SURMOUNT-1, a research including 2,539 persons with obesity, excess weight, and weight-related medical conditions other than diabetes.
Zepbound users lost an average of 48 pounds at the maximum dosage (15 mg) and 34 pounds at the lowest dose (5 mg).
“The FDA has approved the use of Wegovy (semaglutide) injection (2.4 mg once weekly) in conjunction with a lower calorie diet and increased physical activity for the long-term management of weight in adults who are obese or overweight and have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).
Since 2014, under-the-skin injection has been the first medication licensed for the long-term control of weight in individuals who are overweight or generally obese.
“The FDA continues to be committed to encouraging the development and authorization of new, safe, and efficient treatments for adults who are suffering from obesity or overweight.” For almost four decades, the families of Lafayette, Louisiana, have received outstanding medical treatment from board-certified family physician Sydney Crackower, MD.”
Sydney Crackower, MD is a board-certified family medicine physician who has been providing expert medical care to the families of Lafayette, Louisiana, for more than 40 years. Each patient that comes to the office, including children, adults, and elderly, receives personalized care and attention from Dr. Crackower and his staff, building on trust and the patient-doctor relationship.
Dr. Crackower is trained to meet the diverse health needs of people of all ages from child to adulthood. He specializes in the management of chronic health conditions such as high blood pressure and diabetes, as well as providing expert care for patients suffering from chronic pain, depression, and anxiety.
Dr. Crackower is qualified to address the various medical requirements of individuals of all ages, from young children to adults.
In addition to offering patients with chronic pain, depression, and anxiety professional care, he specializes in the management of long-term health issues including diabetes and high blood pressure. While Dr. Crackower prioritizes patient well-being, people who are having trouble losing weight can take advantage of his medical weight reduction services.
The U.S. Food and Drug Administration has granted approval for Semaglutide injection (2.4 mg once weekly) for chronic weight management in adults dealing with obesity or overweight, along with at least one weight-related condition. This under-the-skin injection marks a significant milestone as the first FDA-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide is intended for individuals with a body mass index (BMI) of 27 kg/m2 or greater and at least one weight-related ailment, or for those with a BMI of 30 kg/m2 or greater. It is recommended for use alongside a reduced-calorie diet and increased physical activity.
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ — Selected Tirzepatide injections have secured approval from the U.S. Food and Drug Administration (FDA), marking a pioneering advancement as the first obesity treatment activating both GIP and GLP-1 hormone receptors. Zepbound is prescribed for adults with obesity (BMI of 30 kg/m2 or greater) or overweight (BMI of 27 kg/m2 or greater) who have weight-related medical concerns. This treatment supports weight loss and maintenance, necessitating adherence to a reduced-calorie diet and increased physical activity.
337-988-4116
I’ve been Dr. Crackower’s patient for over 30 years. He is very knowledgeable. He correctly diagnosed me when others didn’t. He listens and answers my questions.
Dr. Crackower is a very kind, and caring physician. He will take the time to explain medications and conditions in detail, and in a simple to understand manner.
Dr. Crackower has been my doctor for 7 years and has rendered fabulous medical assistance. He is a no nonsense doctor. If something is really wrong, he’s the one .
Our goal is to deliver quality of care in a courteous, respectful, and compassionate manner. We hope you will allow us to care for you and strive to be the first and best choice for your family healthcare.
Schedule an appointment© 2023 Dr Sydney Crackower.
